Want to join the conversation?
$MRK 2Q15 Call: In US, excluding Cubist, sales increased 5% primarily from growth in JANUVIA franchise, Oncology and Hospital Acute Care. In Europe and Canada, sales decreased 8%. Japan sales declined 13%. Emerging market sales grew 4% and China grew 8%.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.